Eli Lilly Patent-Cliff Exposure & CMS Drug Spending Portfolio
Eli Lilly (Indianapolis, IN): 68 reconciled FDA prescription therapies, $22.45B 2024 CMS Part D & Medicaid spend, and 27 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Indianapolis, IN |
| Reconciled FDA Portfolio Therapies | 68 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2031-01-01 |
| 2024 CMS Total Public Spend | $22.45B |
| 2024 Medicare Part D Spend | $16.73B |
| 2024 Medicaid Spend | $5.73B |
| California HCAI SB 17 Filings | 27 WAC filings (max 1428.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.